{
  "doc_id": "Hashimoto-Encephalopathy",
  "doc_filename": "Hashimoto-Encephalopathy.pdf",
  "top_entities": [
    {
      "name": "Hashimoto Encephalopathy",
      "mention_count": 1,
      "entity_type": "disease"
    },
    {
      "name": "brain disorder",
      "mention_count": 1,
      "entity_type": "disease"
    },
    {
      "name": "corticosteroids",
      "mention_count": 1,
      "entity_type": "drug"
    }
  ],
  "file_size_bytes": 2315,
  "file_size_human": "2.3 KB",
  "file_extension": ".pdf",
  "pdf_title": "(anonymous)",
  "pdf_author": "(anonymous)",
  "pdf_page_count": 1,
  "pdf_creation_date": "2026-01-07T22:25:18",
  "doi": null,
  "doi_url": null,
  "document_type_code": "CRM",
  "document_type_name": "Clinical Research Materials",
  "document_type_group": "Clinical Research Materials",
  "classification_confidence": 0.15,
  "title": "Hashimoto Encephalopathy: Clinical Overview and Characteristics",
  "short_description": "A comprehensive overview of Hashimoto encephalopathy, a rare immune-mediated disorder characterized by impaired brain function and the presence of antithyroid antibodies.",
  "long_description": "This clinical document provides a detailed examination of Hashimoto encephalopathy, a rare neurological disorder that primarily affects brain function through suspected immune-mediated mechanisms. The document explores the unclear etiology involving antithyroid antibodies, discusses the variable clinical presentation ranging from acute to chronic onset, and highlights the disorder's epidemiological characteristics including its predominance in women and estimated prevalence of 2.1 per 100,000 individuals. The text emphasizes the diagnostic challenges associated with this rare condition and notes the typical therapeutic response to corticosteroid treatment, while acknowledging the limited pediatric cases documented in medical literature.",
  "document_date": "2026-01-07T22:25:18",
  "document_date_source": "pdf_metadata",
  "extraction_timestamp": "2026-02-05T07:04:42.356762"
}